Lutherstadt Wittenberg

This research aims to evaluate the long-term safety and tolerability of pelacarsen (TQJ230) in adults with established cardiovascular disease and elevated Lipoprotein(a) who have completed the parent trial CTQJ230A12301. The study is an open-label extension following the phase 3 parent study, providing participants continued access to pelacarsen after the initial trial. Participants will receive pelacarsen 80 mg by subcutaneous injection once a month during this open-label extension. The study is single-arm and multicenter, focusing on continued treatment with pelacarsen for up to 36 months after completion of the parent study. Throughout the study, participants will be monitored regularly to assess safety and tolerability, with particular attention to adverse events occurring up to 36 months. Researchers will collect data on health status throughout this period to understand the long-term effects of pelacarsen in this patient population.

This research aims to reduce suffering in intensive care units by evaluating the effectiveness and cost-effectiveness of specialized palliative care consultations. The project follows the Europe-wide harmonized and recommended palliative care practices for ICUs as part of the HORIZON-funded EPIC program. It also includes an anonymous employee survey of doctors and nurses during both the intervention and control phases across all study centers. The study involves a complex intervention in the ICU that includes telemedical consultations by specialized palliative care experts from external institutions, training ICU hospital staff in basic palliative care, and using checklists to identify patients early and record their palliative care needs in a structured way. This intervention is compared to routine treatment without these additional palliative care supports. The study uses a cluster-randomized controlled trial design to assess the intervention's impact. Participants are ICU patients aged 18 or older, including those who cannot consent themselves but have authorized representatives. Patients must be newly admitted for more than 72 hours and assessed by the ICU physician for palliative care needs based on specific criteria. Relatives of patients and ICU doctors or nurses involved in palliative care consultations are also included. Researchers will measure outcomes such as the length of intensive care stay, along with surveys of staff, patients, and relatives, to evaluate the intervention's effects.